Stifel thinks Immunic Inc. (IMUX) might have a shot at shaking up the multiple sclerosis drug market. On Thursday, the firm initiated coverage on the late-stage biotech with a Buy rating and a price forecast of $2.50, arguing that the company's lead oral therapy, vidofludimus calcium (IMU-838 or VidoCa), could carve out a meaningful share by doing something simple: being safer.

Here's the play. Immunic's drug is in phase 3 trials for relapsing multiple sclerosis, with top-line data from the twin ENSURE-1 and ENSURE-2 trials expected by the end of 2026. If all goes well, the company plans to submit a marketing application in the U.S. in mid-2027, eyeing a potential regulatory approval in 2028.

Analyst Paul Matteis laid out the core thesis: VidoCa aims to replicate the efficacy of Sanofi SA's (SNY) Aubagio (teriflunomide) while dodging its well-documented safety concerns. Those include hepatotoxicity, alopecia (hair loss), embryofetal toxicity, and neutropenia—issues that have limited broader adoption even though the drug works well. Matteis noted that available data suggests VidoCa has the potential to differentiate across several of these safety parameters. If the phase 3 data validates that, key opinion leaders expect it to become an attractive option, especially for older patients where tolerability and risk management are critical.

Think of it this way: in a market packed with treatments, sometimes you don't need to be the absolute best; you just need to be better on the stuff patients and doctors really worry about. Safety improvements alone could position VidoCa as a viable alternative in a segment sensitive to adverse effects.

Of course, the bear case is obvious: the MS market is incredibly crowded. Skeptics point to the intense competition as a primary risk. But Matteis counters that this isn't new—the space has been packed for over a decade. He highlights that Aubagio still generated more than $2 billion in revenue in 2020 despite competing with therapies like Tecfidera, Gilenya, Tysabri, and the established ABCR class. The historical precedent, he argues, shows that differentiated profiles can still gain traction even in saturated therapeutic areas.

Another concern is how VidoCa would stack up against established giants like Roche Holdings AG's (RHHBY) Ocrevus and a growing pool of generic options. Despite that, key opinion leaders see potential pockets of opportunity if the clinical data holds up. They point to Biogen Inc.'s (BIIB) Vumerity as a conservative benchmark for how newer entrants can establish themselves without directly displacing dominant therapies.

So, it's a bet on safety in a market that's already full. Immunic shares were up 1.00% at $1.01 at the time of publication.